Earnings Beat at Valeant, Guides Up

Zacks

Valeant Pharmaceuticals International’s (VRX) second-quarter 2012 earnings of $1.02 per share (excluding special items but including stock-based compensation expense) was above the Zacks Consensus Estimate of $1.00 and the year-ago earnings of 68 cents per share.

Revenues for the quarter were $820.1 million, up 34.6% from the year-ago period. The year-over-year improvement in revenues was primarily attributable to higher product sales. Total revenues included a milestone payment of $45 million from GlaxoSmithKline (GSK) related to Potiga (ezogabine). Revenues were below the Zacks Consensus Estimate of $830 million.

Quarterly Highlights

Product sales amounted to $748.7 million (on a reported basis) during the second quarter, up 41.3%. Strong sales in the US Dermatology (up 164.6% to $210.6 million), Canada/Australia (up 42.3% to $117.4 million) and the Emerging Markets (up 111.7% to $249 million) segments contributed to the increase. Organically, (excluding the impact of acquisitions and foreign exchange), revenues grew 10% from the year-ago quarter.

Research & development (R&D) expenses fell 0.3% to $17.7 million. Selling, general & administrative (SG&A) expenses for the second quarter increased 23.9% to $185.4 million. While R&D accounted for approximately 2% of revenue, SG&A accounted for 22%.

2012 Guidance

Valeant raised its earnings guidance for 2012. Cash earnings are now expected in the range of $4.55–$4.75 per share (previous guidance: $4.45–$4.70 per share). Excluding one-time items, cash earnings are expected to be between $4.18 and $4.38 per share.

Valeant continues to expect total revenue in the range of $3.4 billion to $3.6 billion. The Zacks Consensus Estimate hinted at 2012 earnings of $4.44 per share on revenues of $3.5 billion.

Recommendation

We currently have a Neutral long-term recommendation on Valeant. The stock carries a Zacks #2 Rank (Buy rating) in the short run.

Read the Full Research Report on VRX

Read the Full Research Report on GSK

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)